Inozyme Pharma (INZY) Competitors $2.79 -0.02 (-0.71%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends INZY vs. ZIOP, FHTX, STML, AVXL, CRMD, TRDA, ABUS, DNTH, PHAT, and EXAIShould you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include ZIOPHARM Oncology (ZIOP), Foghorn Therapeutics (FHTX), Stemline Therapeutics (STML), Anavex Life Sciences (AVXL), CorMedix (CRMD), Entrada Therapeutics (TRDA), Arbutus Biopharma (ABUS), Dianthus Therapeutics (DNTH), Phathom Pharmaceuticals (PHAT), and Exscientia (EXAI). These companies are all part of the "medical" sector. Inozyme Pharma vs. ZIOPHARM Oncology Foghorn Therapeutics Stemline Therapeutics Anavex Life Sciences CorMedix Entrada Therapeutics Arbutus Biopharma Dianthus Therapeutics Phathom Pharmaceuticals Exscientia Inozyme Pharma (NASDAQ:INZY) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends. Which has more risk & volatility, INZY or ZIOP? Inozyme Pharma has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, ZIOPHARM Oncology has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Does the MarketBeat Community believe in INZY or ZIOP? ZIOPHARM Oncology received 340 more outperform votes than Inozyme Pharma when rated by MarketBeat users. However, 86.21% of users gave Inozyme Pharma an outperform vote while only 52.99% of users gave ZIOPHARM Oncology an outperform vote. CompanyUnderperformOutperformInozyme PharmaOutperform Votes5086.21% Underperform Votes813.79%ZIOPHARM OncologyOutperform Votes39052.99% Underperform Votes34647.01% Does the media prefer INZY or ZIOP? In the previous week, Inozyme Pharma had 2 more articles in the media than ZIOPHARM Oncology. MarketBeat recorded 2 mentions for Inozyme Pharma and 0 mentions for ZIOPHARM Oncology. Inozyme Pharma's average media sentiment score of 0.00 equaled ZIOPHARM Oncology'saverage media sentiment score. Company Overall Sentiment Inozyme Pharma Neutral ZIOPHARM Oncology Neutral Do institutionals & insiders have more ownership in INZY or ZIOP? 88.3% of Inozyme Pharma shares are held by institutional investors. Comparatively, 51.0% of ZIOPHARM Oncology shares are held by institutional investors. 11.2% of Inozyme Pharma shares are held by insiders. Comparatively, 5.2% of ZIOPHARM Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer INZY or ZIOP? Inozyme Pharma currently has a consensus price target of $15.71, indicating a potential upside of 463.24%. Given Inozyme Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Inozyme Pharma is more favorable than ZIOPHARM Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inozyme Pharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00ZIOPHARM Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings and valuation, INZY or ZIOP? Inozyme Pharma is trading at a lower price-to-earnings ratio than ZIOPHARM Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInozyme PharmaN/AN/A-$71.17M-$1.56-1.79ZIOPHARM OncologyN/AN/A-$79.98M-$0.43N/A Is INZY or ZIOP more profitable? Inozyme Pharma's return on equity of -88.42% beat ZIOPHARM Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Inozyme PharmaN/A -88.42% -57.02% ZIOPHARM Oncology N/A -92.84%-72.46% SummaryInozyme Pharma beats ZIOPHARM Oncology on 11 of the 14 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INZY vs. The Competition Export to ExcelMetricInozyme PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$180.51M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-1.794.4283.5712.93Price / SalesN/A375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book2.1610.126.936.25Net Income-$71.17M$153.61M$119.12M$225.93M7 Day Performance-18.66%-2.00%-1.83%-1.32%1 Month Performance-47.16%-7.47%-3.64%0.60%1 Year Performance-27.15%31.80%31.64%26.23% Inozyme Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INZYInozyme Pharma1.2302 of 5 stars$2.79-0.7%$15.71+463.2%-28.5%$180.51MN/A-1.7950ZIOPZIOPHARM OncologyN/AN/AN/AN/A$187.12MN/A-2.01105Analyst ForecastFHTXFoghorn Therapeutics2.6424 of 5 stars$7.86+0.8%$16.00+103.6%+91.2%$433.63M$34.15M0.00120STMLStemline TherapeuticsN/A$11.83flatN/A+0.0%$621.21M$43.22M-6.4692AVXLAnavex Life Sciences3.7023 of 5 stars$8.48+2.8%$40.00+372.0%+21.1%$698.72MN/A0.0040Upcoming EarningsCRMDCorMedix2.6748 of 5 stars$10.74-3.0%$15.20+41.5%+184.1%$671.70M$60,000.000.0030Insider TradeTRDAEntrada Therapeutics1.9803 of 5 stars$17.93+0.9%$24.00+33.9%+9.9%$664.95M$129.01M11.28110ABUSArbutus Biopharma2.7999 of 5 stars$3.44-1.4%$5.50+59.9%+87.0%$661.33M$18.14M-8.0073Analyst ForecastDNTHDianthus Therapeutics1.5021 of 5 stars$20.77-6.7%$46.43+123.5%+78.7%$659.12M$2.83M0.0080PHATPhathom Pharmaceuticals2.3252 of 5 stars$8.73-6.8%$22.50+157.7%+17.8%$640.70M$680,000.00-1.53110EXAIExscientia2.2551 of 5 stars$4.84flat$7.00+44.6%N/A$632.93M$25.60M0.00280News Coverage Related Companies and Tools Related Companies ZIOPHARM Oncology Alternatives Foghorn Therapeutics Alternatives Stemline Therapeutics Alternatives Anavex Life Sciences Alternatives CorMedix Alternatives Entrada Therapeutics Alternatives Arbutus Biopharma Alternatives Dianthus Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Exscientia Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INZY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
